Completed PHASE3 INTERVENTIONAL 2-arm NCT00033605

Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy

Sponsor: Alliance for Clinical Trials in Oncology

Conditions Cervical Cancer Colorectal Cancer Diarrhea Endometrial Cancer Fallopian Tube Cancer Ovarian Cancer Prostate Cancer Sarcoma Unspecified Adult Solid Tumor, Protocol Specific Vaginal Cancer Vulvar Cancer

Interventions octreotide acetate placebo radiation

Updated 6 times since 2017 Last updated: Jul 12, 2016 Started: Apr 30, 2002 Primary completion: Jul 31, 2006 Completion: Jul 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00033605, this PHASE3 trial focuses on Cervical Cancer and Colorectal Cancer and remains completed. Sponsored by Alliance for Clinical Trials in Oncology, it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Data source: Alliance for Clinical Trials in Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.